lorcaserin Oral Tablet

Brand(s)
Belviq
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Eisai Inc. (2014-12-16)
Oldest Current Product
2012-06-27
License(s)
NDA
RxNORM
ORAL TABLET\LORCASERIN
FDAOB
ORAL\TABLET\LORCASERIN HYDROCHLORIDE
SPL Active
ORAL\TABLET\LORCASERIN HYDROCHLORIDE HEMIHYDRATE
SPL Moiety
ORAL\TABLET\LORCASERIN

product(s) by strength(s)

lorcaserin hydrochloride 10 mg oral tablet

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1628560529BelviqNDAEisai Inc.2012-06-27LORCASERIN HYDROCHLORIDE HEMIHYDRATEORALTABLETNDA0225297cbbb12f-760d-487d-b789-ae2d52a3e01f

application(s)

#idtitleapplicantapprovedpatentexclusivityapproved drug
1NDA022529BELVIQEISAI INC2012-06-27p8367657, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY, SUBSTANCE
p8207158, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
p8697686, SUBSTANCE
p8946207, SUBSTANCE
p8999970, METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
p6953787, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY, SUBSTANCE
p8980881, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
p8575149, METHOD FOR CHRONIC WEIGHT MANAGEMENT
p8168624, SUBSTANCE
p7977329, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY, SUBSTANCE
p7514422, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
p8273734, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
p8546379, METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE/ METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY, SUBSTANCE
NEW CHEMICAL ENTITY [2017-06-27]NDA022529_001

application drug(s)

#idcategory/deprecatedingredient strength(s)routedose formrldapprovedapplication
1NDA022529_001RXLORCASERIN HYDROCHLORIDE (10MG)ORALTABLETTrue2012-06-27BELVIQ

patent(s)

#idexpiration dateapplication(s)
1p6953787 (view patent)2023-04-10NDA022529
2p7514422 (view patent)2023-04-10NDA022529
3p7977329 (view patent)2023-04-10NDA022529
4p8168624 (view patent)2029-04-18NDA022529
5p8207158 (view patent)2023-04-10NDA022529
6p8273734 (view patent)2023-04-10NDA022529
7p8367657 (view patent)2023-04-10NDA022529
8p8546379 (view patent)2023-04-10NDA022529
9p8575149 (view patent)2023-04-10NDA022529
10p8697686 (view patent)2025-12-20NDA022529
11p8946207 (view patent)2024-06-16NDA022529
12p8980881 (view patent)2025-12-20NDA022529
13p8999970 (view patent)2033-02-07NDA022529

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)
17cbbb12f-760d-487d-b789-ae2d52a3e01f (view SPL)These highlights do not include all the information needed to use BELVIQ safely and effectively. See full prescribing information for BELVIQ. BELVIQ (lorcaserin hydrochloride) tablets, for oral use, CIV Initial U.S. Approval: 2012prescriptionHuman PrescriptionEisai Inc.API MANUFACTURE, MANUFACTURE2014-12-164628560529

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII